Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Enterococcus faecalis | 32 | 2024 | 39 | 13.080 |
Why?
|
Vitamin E | 32 | 2012 | 61 | 6.360 |
Why?
|
Urinary Tract Infections | 19 | 2023 | 35 | 5.360 |
Why?
|
Biofilms | 19 | 2022 | 168 | 5.070 |
Why?
|
Apoptosis | 30 | 2012 | 1398 | 3.670 |
Why?
|
Gram-Positive Bacterial Infections | 10 | 2024 | 17 | 3.310 |
Why?
|
Tocopherols | 29 | 2011 | 65 | 3.000 |
Why?
|
Anti-Bacterial Agents | 13 | 2024 | 352 | 2.770 |
Why?
|
Bacterial Proteins | 17 | 2024 | 540 | 2.710 |
Why?
|
Breast Neoplasms | 27 | 2012 | 1502 | 2.610 |
Why?
|
Antineoplastic Agents | 15 | 2012 | 803 | 2.200 |
Why?
|
Staphylococcus aureus | 3 | 2022 | 75 | 2.160 |
Why?
|
Wound Infection | 7 | 2024 | 7 | 2.160 |
Why?
|
Aminoacyltransferases | 5 | 2022 | 5 | 1.890 |
Why?
|
Escherichia coli Infections | 8 | 2022 | 41 | 1.870 |
Why?
|
Anti-Infective Agents | 3 | 2023 | 64 | 1.740 |
Why?
|
Fimbriae, Bacterial | 9 | 2022 | 23 | 1.630 |
Why?
|
Fimbriae Proteins | 9 | 2022 | 21 | 1.610 |
Why?
|
Gram-Positive Bacteria | 3 | 2016 | 14 | 1.460 |
Why?
|
Virulence Factors | 8 | 2020 | 113 | 1.400 |
Why?
|
Disease Models, Animal | 11 | 2024 | 1371 | 1.350 |
Why?
|
Escherichia coli | 6 | 2022 | 453 | 1.340 |
Why?
|
Streptococcus pyogenes | 2 | 2019 | 27 | 1.330 |
Why?
|
Urinary Tract | 4 | 2019 | 8 | 1.310 |
Why?
|
Bacterial Infections | 2 | 2021 | 43 | 1.300 |
Why?
|
alpha-Tocopherol | 8 | 2012 | 27 | 1.290 |
Why?
|
Streptococcal Infections | 4 | 2019 | 34 | 1.280 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 10 | 2012 | 77 | 1.270 |
Why?
|
Mice | 31 | 2024 | 5913 | 1.270 |
Why?
|
Animals | 48 | 2024 | 15081 | 1.260 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 5 | 2012 | 9 | 1.260 |
Why?
|
Neisseria gonorrhoeae | 7 | 2007 | 15 | 1.240 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 5 | 2024 | 56 | 1.230 |
Why?
|
Host-Pathogen Interactions | 3 | 2016 | 186 | 1.170 |
Why?
|
Microbial Interactions | 2 | 2016 | 10 | 1.120 |
Why?
|
Daptomycin | 2 | 2024 | 2 | 1.110 |
Why?
|
Membrane Proteins | 2 | 2022 | 517 | 1.070 |
Why?
|
Antimicrobial Cationic Peptides | 3 | 2023 | 35 | 1.060 |
Why?
|
Cysteine Endopeptidases | 5 | 2013 | 59 | 1.030 |
Why?
|
Catheter-Related Infections | 5 | 2018 | 11 | 1.020 |
Why?
|
Adhesins, Bacterial | 2 | 2018 | 20 | 1.000 |
Why?
|
Staphylococcal Infections | 3 | 2017 | 58 | 0.990 |
Why?
|
Escherichia coli Proteins | 3 | 2022 | 126 | 0.990 |
Why?
|
Uropathogenic Escherichia coli | 5 | 2020 | 8 | 0.990 |
Why?
|
Humans | 67 | 2024 | 37093 | 0.990 |
Why?
|
Streptococcus agalactiae | 3 | 2014 | 10 | 0.950 |
Why?
|
Peptide Hydrolases | 1 | 2024 | 40 | 0.950 |
Why?
|
Cell Line, Tumor | 18 | 2012 | 2231 | 0.940 |
Why?
|
Cell Division | 17 | 2020 | 307 | 0.920 |
Why?
|
Tumor Cells, Cultured | 21 | 2010 | 502 | 0.860 |
Why?
|
Iron | 3 | 2022 | 225 | 0.860 |
Why?
|
Phosphotransferases | 1 | 2022 | 35 | 0.850 |
Why?
|
Signal Transduction | 14 | 2017 | 1908 | 0.850 |
Why?
|
Mammary Neoplasms, Experimental | 3 | 2009 | 70 | 0.840 |
Why?
|
rab GTP-Binding Proteins | 1 | 2022 | 12 | 0.830 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 5 | 2010 | 29 | 0.810 |
Why?
|
Pseudomonas aeruginosa | 1 | 2022 | 57 | 0.810 |
Why?
|
Health Education | 3 | 2016 | 338 | 0.800 |
Why?
|
Recombination, Genetic | 5 | 2007 | 93 | 0.790 |
Why?
|
Adenosine Triphosphatases | 3 | 2013 | 82 | 0.780 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2011 | 182 | 0.760 |
Why?
|
DNA-Binding Proteins | 4 | 2011 | 539 | 0.740 |
Why?
|
gamma-Tocopherol | 2 | 2012 | 19 | 0.740 |
Why?
|
Transforming Growth Factor beta | 9 | 2002 | 197 | 0.740 |
Why?
|
Staphylococcus | 3 | 2022 | 9 | 0.730 |
Why?
|
Transcription Factor CHOP | 4 | 2012 | 11 | 0.730 |
Why?
|
Transcription Factors | 3 | 2022 | 681 | 0.700 |
Why?
|
Female | 39 | 2016 | 20969 | 0.700 |
Why?
|
Endoplasmic Reticulum | 2 | 2010 | 105 | 0.690 |
Why?
|
Lung Neoplasms | 5 | 2008 | 358 | 0.680 |
Why?
|
Manganese | 1 | 2020 | 87 | 0.680 |
Why?
|
Enterococcus | 1 | 2019 | 6 | 0.670 |
Why?
|
Immune System | 1 | 2019 | 41 | 0.670 |
Why?
|
Proto-Oncogene Proteins c-jun | 6 | 2008 | 26 | 0.670 |
Why?
|
Immune Tolerance | 2 | 2017 | 65 | 0.660 |
Why?
|
Nuclear Proteins | 3 | 2011 | 307 | 0.660 |
Why?
|
Streptolysins | 1 | 2018 | 4 | 0.660 |
Why?
|
Virulence | 5 | 2022 | 223 | 0.660 |
Why?
|
Mice, Inbred C57BL | 13 | 2024 | 1609 | 0.660 |
Why?
|
Fasciitis, Necrotizing | 1 | 2018 | 11 | 0.650 |
Why?
|
MAP Kinase Kinase 4 | 6 | 2011 | 31 | 0.640 |
Why?
|
Disease Susceptibility | 2 | 2015 | 97 | 0.630 |
Why?
|
Electron Transport | 1 | 2018 | 40 | 0.620 |
Why?
|
Immune Evasion | 1 | 2017 | 16 | 0.620 |
Why?
|
Tumor Suppressor Proteins | 2 | 2011 | 194 | 0.610 |
Why?
|
Enterococcus faecium | 1 | 2017 | 1 | 0.600 |
Why?
|
Antioxidants | 7 | 2012 | 416 | 0.590 |
Why?
|
Ornithine | 1 | 2016 | 1 | 0.580 |
Why?
|
Urinary Catheterization | 1 | 2016 | 4 | 0.570 |
Why?
|
Antibiotic Prophylaxis | 1 | 2016 | 7 | 0.570 |
Why?
|
Macrophages | 7 | 2024 | 439 | 0.570 |
Why?
|
Bacteriuria | 1 | 2016 | 2 | 0.560 |
Why?
|
Membrane Microdomains | 2 | 2017 | 47 | 0.550 |
Why?
|
Breast Self-Examination | 3 | 2000 | 12 | 0.540 |
Why?
|
Blotting, Western | 10 | 2012 | 859 | 0.540 |
Why?
|
Chromans | 2 | 2012 | 15 | 0.540 |
Why?
|
Sulfonamides | 2 | 2008 | 80 | 0.530 |
Why?
|
DNA Helicases | 3 | 2006 | 41 | 0.530 |
Why?
|
Membrane Transport Proteins | 2 | 2013 | 95 | 0.520 |
Why?
|
Mice, Inbred C3H | 7 | 2013 | 84 | 0.520 |
Why?
|
Bacterial Adhesion | 5 | 2020 | 37 | 0.500 |
Why?
|
Self Care | 1 | 2016 | 159 | 0.490 |
Why?
|
DNA, Neoplasm | 7 | 2004 | 92 | 0.490 |
Why?
|
Urinary Bladder | 6 | 2016 | 29 | 0.490 |
Why?
|
DNA, Bacterial | 6 | 2017 | 186 | 0.480 |
Why?
|
Parity | 1 | 2014 | 46 | 0.480 |
Why?
|
beta-Defensins | 1 | 2013 | 4 | 0.470 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 4 | 2010 | 152 | 0.470 |
Why?
|
DNA Repair | 3 | 2006 | 188 | 0.450 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 2 | 2010 | 10 | 0.450 |
Why?
|
Cell Survival | 6 | 2024 | 864 | 0.440 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2003 | 136 | 0.440 |
Why?
|
Drug Resistance, Bacterial | 2 | 2024 | 77 | 0.440 |
Why?
|
Antigenic Variation | 3 | 2007 | 9 | 0.430 |
Why?
|
Docosahexaenoic Acids | 1 | 2012 | 18 | 0.420 |
Why?
|
Ceramides | 1 | 2012 | 42 | 0.420 |
Why?
|
Transformation, Genetic | 2 | 2016 | 21 | 0.400 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2011 | 33 | 0.400 |
Why?
|
Fas Ligand Protein | 2 | 2008 | 16 | 0.400 |
Why?
|
Tamoxifen | 1 | 2011 | 65 | 0.390 |
Why?
|
RNA, Small Interfering | 5 | 2012 | 409 | 0.390 |
Why?
|
Vancomycin | 2 | 2023 | 5 | 0.390 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2012 | 1039 | 0.390 |
Why?
|
Anticarcinogenic Agents | 2 | 2004 | 65 | 0.390 |
Why?
|
Mass Media | 4 | 2013 | 35 | 0.390 |
Why?
|
Aging | 2 | 2015 | 664 | 0.390 |
Why?
|
1-Phosphatidylinositol 4-Kinase | 1 | 2010 | 2 | 0.380 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2010 | 20 | 0.380 |
Why?
|
Phosphatidylglycerols | 2 | 2023 | 11 | 0.370 |
Why?
|
Prostatic Neoplasms | 3 | 2008 | 935 | 0.370 |
Why?
|
Vitamins | 3 | 2008 | 94 | 0.370 |
Why?
|
Cisplatin | 2 | 2011 | 72 | 0.370 |
Why?
|
Cholesterol | 1 | 2011 | 205 | 0.370 |
Why?
|
Tocotrienols | 1 | 2010 | 2 | 0.360 |
Why?
|
Gram-Negative Bacteria | 1 | 2010 | 22 | 0.360 |
Why?
|
Pyrazoles | 2 | 2008 | 85 | 0.360 |
Why?
|
RNA, Messenger | 11 | 2012 | 1207 | 0.360 |
Why?
|
Mitochondria | 4 | 2008 | 487 | 0.340 |
Why?
|
Liposomes | 5 | 2009 | 118 | 0.340 |
Why?
|
Gastrointestinal Tract | 2 | 2020 | 61 | 0.340 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2011 | 222 | 0.330 |
Why?
|
RNA Interference | 4 | 2012 | 243 | 0.330 |
Why?
|
Pamphlets | 2 | 2007 | 26 | 0.330 |
Why?
|
Mammary Neoplasms, Animal | 2 | 2008 | 30 | 0.320 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2011 | 213 | 0.320 |
Why?
|
Stress, Physiological | 1 | 2010 | 150 | 0.320 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2016 | 643 | 0.320 |
Why?
|
Caspase 8 | 4 | 2010 | 32 | 0.320 |
Why?
|
Bibliometrics | 2 | 2013 | 17 | 0.320 |
Why?
|
Neoplasm Metastasis | 1 | 2009 | 219 | 0.310 |
Why?
|
Organoselenium Compounds | 1 | 2008 | 10 | 0.310 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2019 | 30 | 0.310 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2008 | 22 | 0.310 |
Why?
|
Lymphatic Metastasis | 4 | 2009 | 65 | 0.300 |
Why?
|
Stilbenes | 1 | 2008 | 44 | 0.300 |
Why?
|
Ultraviolet Rays | 1 | 2008 | 117 | 0.300 |
Why?
|
Mammography | 2 | 2007 | 188 | 0.300 |
Why?
|
Health Services Research | 2 | 2006 | 148 | 0.300 |
Why?
|
Drug Screening Assays, Antitumor | 4 | 2012 | 113 | 0.300 |
Why?
|
Proteome | 2 | 2023 | 144 | 0.290 |
Why?
|
Mutation | 5 | 2024 | 1095 | 0.290 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2007 | 49 | 0.290 |
Why?
|
Thymus Neoplasms | 2 | 1997 | 4 | 0.280 |
Why?
|
Health Promotion | 2 | 2006 | 653 | 0.280 |
Why?
|
Mice, Inbred BALB C | 4 | 2010 | 661 | 0.280 |
Why?
|
Metals | 2 | 2020 | 98 | 0.270 |
Why?
|
Lactic Acid | 2 | 2022 | 95 | 0.270 |
Why?
|
Bacteria | 1 | 2009 | 255 | 0.270 |
Why?
|
Skin Neoplasms | 1 | 2008 | 159 | 0.270 |
Why?
|
Enzyme Activation | 5 | 2007 | 444 | 0.270 |
Why?
|
Lymphocyte Activation | 4 | 2011 | 236 | 0.270 |
Why?
|
Microbial Sensitivity Tests | 2 | 2024 | 201 | 0.260 |
Why?
|
Kidney | 4 | 2012 | 337 | 0.260 |
Why?
|
Cyclins | 2 | 2002 | 37 | 0.260 |
Why?
|
Neutrophils | 3 | 2011 | 131 | 0.250 |
Why?
|
Mammals | 2 | 2023 | 105 | 0.250 |
Why?
|
Camptothecin | 1 | 2004 | 20 | 0.250 |
Why?
|
Tumor Burden | 3 | 2010 | 77 | 0.250 |
Why?
|
Acute Disease | 2 | 2015 | 147 | 0.250 |
Why?
|
CASP8 and FADD-Like Apoptosis Regulating Protein | 3 | 2010 | 8 | 0.250 |
Why?
|
Promoter Regions, Genetic | 1 | 2007 | 515 | 0.240 |
Why?
|
Ovarian Neoplasms | 2 | 2006 | 312 | 0.240 |
Why?
|
Cell Wall | 2 | 2022 | 53 | 0.240 |
Why?
|
Proto-Oncogene Proteins | 2 | 2003 | 239 | 0.240 |
Why?
|
Aniline Compounds | 1 | 2024 | 23 | 0.240 |
Why?
|
Time Factors | 5 | 2010 | 1742 | 0.240 |
Why?
|
Polymers | 2 | 2020 | 121 | 0.240 |
Why?
|
Cell Cycle Proteins | 2 | 2020 | 229 | 0.230 |
Why?
|
Keratinocytes | 1 | 2024 | 66 | 0.230 |
Why?
|
Phagocytosis | 1 | 2024 | 69 | 0.230 |
Why?
|
Carbohydrates | 1 | 2023 | 29 | 0.230 |
Why?
|
Cross Infection | 2 | 2015 | 38 | 0.230 |
Why?
|
Purines | 1 | 2023 | 38 | 0.230 |
Why?
|
Drug Synergism | 4 | 2010 | 177 | 0.230 |
Why?
|
Pyelonephritis | 2 | 2014 | 3 | 0.230 |
Why?
|
Up-Regulation | 3 | 2012 | 513 | 0.230 |
Why?
|
Self Efficacy | 3 | 2016 | 184 | 0.230 |
Why?
|
Neisseria meningitidis | 1 | 2003 | 16 | 0.230 |
Why?
|
MAP Kinase Signaling System | 2 | 2002 | 169 | 0.230 |
Why?
|
Wound Healing | 1 | 2024 | 70 | 0.230 |
Why?
|
Vancomycin Resistance | 1 | 2023 | 2 | 0.220 |
Why?
|
Mitoxantrone | 1 | 2023 | 3 | 0.220 |
Why?
|
Transcription Factor AP-1 | 3 | 1998 | 35 | 0.220 |
Why?
|
Phosphorylation | 4 | 2011 | 928 | 0.220 |
Why?
|
Cell Proliferation | 4 | 2010 | 1198 | 0.220 |
Why?
|
Neoplasm Proteins | 3 | 2012 | 213 | 0.220 |
Why?
|
Poly(ADP-ribose) Polymerases | 4 | 2010 | 78 | 0.220 |
Why?
|
Nanoparticles | 1 | 2007 | 318 | 0.220 |
Why?
|
Cations | 1 | 2023 | 45 | 0.220 |
Why?
|
Male | 12 | 2024 | 20025 | 0.220 |
Why?
|
Microbial Viability | 2 | 2016 | 37 | 0.220 |
Why?
|
Caspases | 3 | 2010 | 147 | 0.210 |
Why?
|
Protein Transport | 2 | 2016 | 302 | 0.210 |
Why?
|
DNA Replication | 1 | 2003 | 152 | 0.210 |
Why?
|
Patient Acceptance of Health Care | 1 | 2007 | 404 | 0.210 |
Why?
|
N-Methylaspartate | 1 | 2022 | 57 | 0.210 |
Why?
|
Cell Cycle | 2 | 2002 | 326 | 0.210 |
Why?
|
Gene Expression | 5 | 2020 | 674 | 0.210 |
Why?
|
Phospholipids | 1 | 2023 | 70 | 0.210 |
Why?
|
Endosomes | 1 | 2022 | 36 | 0.210 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 6 | 0.210 |
Why?
|
Doxycycline | 1 | 2002 | 30 | 0.210 |
Why?
|
Fatty Acids | 1 | 2023 | 127 | 0.200 |
Why?
|
Heme | 1 | 2022 | 70 | 0.200 |
Why?
|
Mutagens | 1 | 2022 | 69 | 0.200 |
Why?
|
Aerosols | 3 | 2009 | 48 | 0.200 |
Why?
|
Cell Membrane | 2 | 2016 | 381 | 0.200 |
Why?
|
Cytokines | 3 | 2011 | 602 | 0.200 |
Why?
|
Lysosomes | 1 | 2022 | 91 | 0.200 |
Why?
|
Oligonucleotides, Antisense | 4 | 2003 | 39 | 0.200 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2012 | 807 | 0.200 |
Why?
|
Drug Carriers | 2 | 2018 | 125 | 0.200 |
Why?
|
Carbon | 1 | 2022 | 105 | 0.200 |
Why?
|
Gene Expression Regulation, Bacterial | 4 | 2017 | 149 | 0.200 |
Why?
|
Protein Kinases | 2 | 1999 | 100 | 0.200 |
Why?
|
Growth Inhibitors | 1 | 2001 | 26 | 0.190 |
Why?
|
Genes, Essential | 1 | 2020 | 5 | 0.190 |
Why?
|
Biological Transport | 2 | 2020 | 185 | 0.190 |
Why?
|
Cell Differentiation | 3 | 2002 | 587 | 0.190 |
Why?
|
Carrier Proteins | 1 | 2023 | 305 | 0.190 |
Why?
|
DNA Primers | 2 | 2013 | 286 | 0.190 |
Why?
|
Journalism, Medical | 2 | 2013 | 5 | 0.190 |
Why?
|
Models, Theoretical | 2 | 2018 | 217 | 0.190 |
Why?
|
Molecular Sequence Data | 5 | 2007 | 1568 | 0.180 |
Why?
|
Immunosuppressive Agents | 3 | 2010 | 76 | 0.180 |
Why?
|
Intracellular Space | 1 | 2020 | 35 | 0.180 |
Why?
|
Reactive Oxygen Species | 3 | 2024 | 461 | 0.180 |
Why?
|
Quorum Sensing | 1 | 2020 | 13 | 0.180 |
Why?
|
Cell Line | 4 | 2018 | 1354 | 0.180 |
Why?
|
Base Sequence | 4 | 2008 | 997 | 0.180 |
Why?
|
Peptides | 1 | 2022 | 320 | 0.170 |
Why?
|
Drug Therapy, Combination | 3 | 2012 | 227 | 0.170 |
Why?
|
NF-kappa B | 2 | 2024 | 339 | 0.170 |
Why?
|
Blood | 1 | 2019 | 37 | 0.170 |
Why?
|
Adaptive Immunity | 1 | 2019 | 27 | 0.170 |
Why?
|
Fenretinide | 1 | 1999 | 8 | 0.170 |
Why?
|
Endocarditis, Bacterial | 1 | 2018 | 5 | 0.170 |
Why?
|
Bacteriological Techniques | 1 | 2018 | 14 | 0.170 |
Why?
|
Risk Factors | 3 | 2015 | 3562 | 0.170 |
Why?
|
Gene Transfer, Horizontal | 1 | 2018 | 24 | 0.170 |
Why?
|
Pheromones | 1 | 2018 | 18 | 0.160 |
Why?
|
Inflammation | 2 | 2016 | 618 | 0.160 |
Why?
|
Administration, Inhalation | 2 | 2009 | 80 | 0.160 |
Why?
|
Homeostasis | 1 | 2020 | 188 | 0.160 |
Why?
|
Extracellular Matrix | 1 | 2019 | 115 | 0.160 |
Why?
|
Lymph Nodes | 2 | 2009 | 67 | 0.160 |
Why?
|
Cell Adhesion | 2 | 2020 | 212 | 0.160 |
Why?
|
Immunity, Innate | 1 | 2019 | 149 | 0.160 |
Why?
|
Polyesters | 1 | 2018 | 25 | 0.160 |
Why?
|
Delayed-Action Preparations | 1 | 2018 | 60 | 0.160 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2018 | 62 | 0.160 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 623 | 0.150 |
Why?
|
Adaptation, Psychological | 1 | 2000 | 385 | 0.150 |
Why?
|
Cell Nucleus | 2 | 2011 | 366 | 0.150 |
Why?
|
Nitriles | 2 | 2024 | 69 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2011 | 269 | 0.150 |
Why?
|
Inhibitor of Apoptosis Proteins | 2 | 2008 | 32 | 0.150 |
Why?
|
Heart | 1 | 2019 | 180 | 0.150 |
Why?
|
Prospective Studies | 1 | 2021 | 1378 | 0.150 |
Why?
|
Enterobactin | 1 | 2016 | 1 | 0.140 |
Why?
|
Fear | 1 | 2000 | 249 | 0.140 |
Why?
|
Energy Metabolism | 1 | 2018 | 168 | 0.140 |
Why?
|
Microtubule-Associated Proteins | 2 | 2008 | 85 | 0.140 |
Why?
|
Lymphoma | 1 | 1997 | 38 | 0.140 |
Why?
|
Transformation, Bacterial | 3 | 2006 | 12 | 0.140 |
Why?
|
Lysine | 1 | 2017 | 113 | 0.140 |
Why?
|
Health Behavior | 1 | 2000 | 537 | 0.140 |
Why?
|
Protein Sorting Signals | 1 | 2016 | 26 | 0.140 |
Why?
|
Bone Marrow | 2 | 1995 | 37 | 0.140 |
Why?
|
Thymoma | 1 | 1996 | 1 | 0.140 |
Why?
|
Television | 1 | 2016 | 28 | 0.140 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 95 | 0.140 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 202 | 0.140 |
Why?
|
Culture Media, Conditioned | 4 | 1997 | 46 | 0.140 |
Why?
|
Models, Biological | 2 | 2010 | 677 | 0.140 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 2016 | 52 | 0.130 |
Why?
|
Chromatography, Liquid | 2 | 2017 | 142 | 0.130 |
Why?
|
Pneumonia, Bacterial | 1 | 2015 | 22 | 0.130 |
Why?
|
Leukemia, Promyelocytic, Acute | 2 | 1995 | 19 | 0.130 |
Why?
|
Disinfection | 1 | 2015 | 9 | 0.130 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2009 | 110 | 0.130 |
Why?
|
Enzyme Inhibitors | 2 | 2010 | 433 | 0.130 |
Why?
|
bcl-2-Associated X Protein | 2 | 2007 | 77 | 0.130 |
Why?
|
Mice, Nude | 2 | 2008 | 337 | 0.130 |
Why?
|
Water Purification | 1 | 2015 | 28 | 0.130 |
Why?
|
Receptors, Transforming Growth Factor beta | 3 | 2004 | 24 | 0.130 |
Why?
|
Chitosan | 1 | 2015 | 36 | 0.130 |
Why?
|
Tandem Mass Spectrometry | 2 | 2017 | 182 | 0.130 |
Why?
|
Bone Marrow Neoplasms | 1 | 1995 | 1 | 0.130 |
Why?
|
Receptors, Fibronectin | 1 | 1995 | 3 | 0.130 |
Why?
|
Water Microbiology | 1 | 2015 | 76 | 0.130 |
Why?
|
Allergy and Immunology | 1 | 1995 | 11 | 0.130 |
Why?
|
Administration, Oral | 2 | 2007 | 224 | 0.130 |
Why?
|
Cultural Diversity | 2 | 2007 | 169 | 0.130 |
Why?
|
Nutritional Physiological Phenomena | 1 | 1995 | 39 | 0.120 |
Why?
|
Graphite | 1 | 2015 | 51 | 0.120 |
Why?
|
Blotting, Northern | 3 | 2002 | 150 | 0.120 |
Why?
|
Spleen | 3 | 1989 | 199 | 0.120 |
Why?
|
Receptors, Estrogen | 2 | 2011 | 156 | 0.120 |
Why?
|
Fibronectins | 1 | 1995 | 66 | 0.120 |
Why?
|
Program Evaluation | 1 | 2016 | 339 | 0.120 |
Why?
|
Smoking Cessation | 1 | 2021 | 517 | 0.120 |
Why?
|
Cystitis | 1 | 2014 | 8 | 0.120 |
Why?
|
Aged | 3 | 2016 | 6741 | 0.120 |
Why?
|
Meningococcal Vaccines | 1 | 2013 | 7 | 0.120 |
Why?
|
Amino Acid Sequence | 3 | 2005 | 1180 | 0.120 |
Why?
|
Hydro-Lyases | 1 | 2013 | 11 | 0.120 |
Why?
|
Toll-Like Receptor 4 | 1 | 2014 | 62 | 0.120 |
Why?
|
Nanostructures | 1 | 2015 | 134 | 0.120 |
Why?
|
Kinetics | 2 | 2008 | 708 | 0.110 |
Why?
|
Transfection | 3 | 2002 | 523 | 0.110 |
Why?
|
Serine | 1 | 2013 | 75 | 0.110 |
Why?
|
Fluorescent Antibody Technique | 1 | 2013 | 189 | 0.110 |
Why?
|
Mannosides | 1 | 2012 | 3 | 0.110 |
Why?
|
Caspases, Initiator | 1 | 2012 | 4 | 0.110 |
Why?
|
Molecular Weight | 4 | 2012 | 167 | 0.110 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2012 | 22 | 0.110 |
Why?
|
Internet | 1 | 2013 | 211 | 0.100 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2002 | 55 | 0.100 |
Why?
|
beta-Cyclodextrins | 1 | 2011 | 24 | 0.100 |
Why?
|
Sialic Acids | 1 | 2011 | 3 | 0.100 |
Why?
|
Bacterial Capsules | 1 | 2011 | 6 | 0.100 |
Why?
|
Age Factors | 2 | 2014 | 1033 | 0.100 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 2 | 2002 | 103 | 0.100 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2002 | 99 | 0.100 |
Why?
|
Papillomavirus Vaccines | 1 | 2013 | 151 | 0.100 |
Why?
|
Structure-Activity Relationship | 1 | 2012 | 409 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2011 | 8 | 0.100 |
Why?
|
Anthracenes | 1 | 2010 | 13 | 0.100 |
Why?
|
Butadienes | 1 | 2010 | 29 | 0.100 |
Why?
|
Androstadienes | 1 | 2010 | 18 | 0.100 |
Why?
|
Chronic Disease | 1 | 2014 | 484 | 0.090 |
Why?
|
Molecular Structure | 1 | 2012 | 492 | 0.090 |
Why?
|
Sirolimus | 1 | 2010 | 60 | 0.090 |
Why?
|
Receptors, Progesterone | 1 | 2011 | 81 | 0.090 |
Why?
|
Doxorubicin | 1 | 2011 | 84 | 0.090 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2010 | 76 | 0.090 |
Why?
|
Histocytochemistry | 1 | 2010 | 50 | 0.090 |
Why?
|
Colony Count, Microbial | 1 | 2010 | 66 | 0.090 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 474 | 0.090 |
Why?
|
Retroviridae Proteins, Oncogenic | 1 | 1990 | 27 | 0.090 |
Why?
|
Microscopy | 1 | 2010 | 32 | 0.090 |
Why?
|
N-Acetylmuramoyl-L-alanine Amidase | 1 | 2009 | 2 | 0.090 |
Why?
|
Aged, 80 and over | 1 | 2015 | 2379 | 0.090 |
Why?
|
Receptor, erbB-2 | 1 | 2011 | 133 | 0.090 |
Why?
|
Reticuloendotheliosis virus | 1 | 1989 | 2 | 0.090 |
Why?
|
Transcriptional Activation | 2 | 2001 | 172 | 0.090 |
Why?
|
Tumor Virus Infections | 1 | 1989 | 26 | 0.090 |
Why?
|
Green Fluorescent Proteins | 2 | 2008 | 208 | 0.080 |
Why?
|
Neoplasms | 2 | 2001 | 1103 | 0.080 |
Why?
|
Paclitaxel | 1 | 2009 | 50 | 0.080 |
Why?
|
Lymphocytes | 2 | 2007 | 118 | 0.080 |
Why?
|
Models, Molecular | 1 | 2012 | 808 | 0.080 |
Why?
|
Immunoblotting | 1 | 2009 | 176 | 0.080 |
Why?
|
Models, Chemical | 1 | 2010 | 207 | 0.080 |
Why?
|
Middle Aged | 4 | 2017 | 10129 | 0.080 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2009 | 146 | 0.080 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2008 | 41 | 0.080 |
Why?
|
Neovascularization, Pathologic | 1 | 2009 | 127 | 0.080 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2008 | 22 | 0.080 |
Why?
|
Fas-Associated Death Domain Protein | 1 | 2008 | 3 | 0.080 |
Why?
|
Cell Death | 1 | 2009 | 267 | 0.080 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2008 | 2 | 0.080 |
Why?
|
Mice, Hairless | 1 | 2008 | 7 | 0.080 |
Why?
|
Mannosephosphates | 2 | 1999 | 2 | 0.080 |
Why?
|
Co-Repressor Proteins | 1 | 2008 | 16 | 0.080 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 252 | 0.080 |
Why?
|
Morpholines | 1 | 2008 | 69 | 0.080 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2008 | 30 | 0.080 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2007 | 7 | 0.080 |
Why?
|
Sequence Alignment | 2 | 2005 | 265 | 0.080 |
Why?
|
Acetates | 1 | 2008 | 21 | 0.080 |
Why?
|
Caspase 9 | 1 | 2007 | 30 | 0.080 |
Why?
|
Radiation Dosage | 1 | 2008 | 37 | 0.080 |
Why?
|
Chromones | 1 | 2008 | 54 | 0.080 |
Why?
|
Antigens, Bacterial | 3 | 2006 | 132 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1989 | 172 | 0.080 |
Why?
|
Cytochromes c | 1 | 2007 | 53 | 0.080 |
Why?
|
Permeability | 1 | 2007 | 67 | 0.080 |
Why?
|
Forkhead Transcription Factors | 1 | 2008 | 76 | 0.080 |
Why?
|
Molecular Chaperones | 1 | 2008 | 61 | 0.080 |
Why?
|
Phosphatidylcholines | 1 | 2007 | 47 | 0.080 |
Why?
|
Polyglycolic Acid | 1 | 2007 | 37 | 0.080 |
Why?
|
Mitochondrial Membranes | 1 | 2007 | 40 | 0.070 |
Why?
|
Mammary Glands, Human | 1 | 2007 | 39 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2008 | 259 | 0.070 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 2007 | 31 | 0.070 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2008 | 94 | 0.070 |
Why?
|
Mutagenesis, Insertional | 1 | 2007 | 32 | 0.070 |
Why?
|
Carcinoma | 1 | 2008 | 96 | 0.070 |
Why?
|
Immunohistochemistry | 1 | 2009 | 893 | 0.070 |
Why?
|
Particle Size | 1 | 2007 | 215 | 0.070 |
Why?
|
DNA Transposable Elements | 1 | 2007 | 48 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-fos | 2 | 1997 | 82 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2008 | 128 | 0.070 |
Why?
|
Sequence Deletion | 1 | 2007 | 87 | 0.070 |
Why?
|
Oncogene Protein v-akt | 1 | 2006 | 20 | 0.070 |
Why?
|
Skin | 1 | 2008 | 174 | 0.070 |
Why?
|
DNA, Cruciform | 1 | 2006 | 3 | 0.070 |
Why?
|
Social Perception | 1 | 2007 | 62 | 0.070 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2008 | 190 | 0.070 |
Why?
|
Social Identification | 1 | 2007 | 58 | 0.070 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 93 | 0.070 |
Why?
|
Social Conditions | 1 | 2006 | 12 | 0.070 |
Why?
|
Benzene Derivatives | 1 | 2005 | 4 | 0.070 |
Why?
|
Cell Transformation, Viral | 2 | 1999 | 29 | 0.070 |
Why?
|
Oxidants | 1 | 2005 | 45 | 0.070 |
Why?
|
Antibodies | 2 | 1997 | 141 | 0.070 |
Why?
|
Free Radicals | 1 | 2005 | 74 | 0.070 |
Why?
|
Body Weight | 1 | 2007 | 434 | 0.060 |
Why?
|
Forecasting | 1 | 2006 | 128 | 0.060 |
Why?
|
Phytohemagglutinins | 2 | 1984 | 13 | 0.060 |
Why?
|
Concanavalin A | 2 | 1984 | 10 | 0.060 |
Why?
|
Chemoprevention | 1 | 2004 | 35 | 0.060 |
Why?
|
Nitrophenols | 1 | 2004 | 4 | 0.060 |
Why?
|
Neoplasms, Experimental | 1 | 2004 | 37 | 0.060 |
Why?
|
Esterases | 1 | 2004 | 7 | 0.060 |
Why?
|
Muscular Dystrophy, Animal | 1 | 1984 | 3 | 0.060 |
Why?
|
Transplantation, Heterologous | 1 | 2004 | 90 | 0.060 |
Why?
|
Down-Regulation | 1 | 2006 | 435 | 0.060 |
Why?
|
Hydrogen Peroxide | 1 | 2005 | 190 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2008 | 626 | 0.060 |
Why?
|
Adenocarcinoma | 1 | 2006 | 251 | 0.060 |
Why?
|
Communication | 1 | 2006 | 180 | 0.060 |
Why?
|
Drug Interactions | 1 | 2004 | 141 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2007 | 322 | 0.060 |
Why?
|
Treatment Outcome | 1 | 2008 | 1369 | 0.060 |
Why?
|
Quinolines | 1 | 2024 | 64 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2004 | 78 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2021 | 864 | 0.060 |
Why?
|
Cytochrome c Group | 1 | 2003 | 16 | 0.060 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2023 | 29 | 0.060 |
Why?
|
Heat-Shock Proteins | 1 | 2023 | 55 | 0.060 |
Why?
|
Gene Expression Regulation | 2 | 2002 | 1015 | 0.060 |
Why?
|
Adenosine | 1 | 2023 | 59 | 0.060 |
Why?
|
Cytosol | 1 | 2003 | 93 | 0.060 |
Why?
|
In Situ Nick-End Labeling | 1 | 2003 | 133 | 0.060 |
Why?
|
Retroviridae | 2 | 1995 | 22 | 0.050 |
Why?
|
DNA Damage | 1 | 2005 | 352 | 0.050 |
Why?
|
Genes, jun | 1 | 2002 | 8 | 0.050 |
Why?
|
Fibroblasts | 1 | 2024 | 272 | 0.050 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2002 | 14 | 0.050 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 17 | 0.050 |
Why?
|
Keratins | 1 | 2002 | 25 | 0.050 |
Why?
|
Gene Deletion | 3 | 2012 | 166 | 0.050 |
Why?
|
Translocation, Genetic | 1 | 2002 | 42 | 0.050 |
Why?
|
Luciferases | 1 | 2002 | 63 | 0.050 |
Why?
|
Activating Transcription Factor 2 | 1 | 2001 | 3 | 0.050 |
Why?
|
ets-Domain Protein Elk-1 | 1 | 2001 | 28 | 0.050 |
Why?
|
United States | 2 | 2013 | 4223 | 0.050 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2001 | 54 | 0.050 |
Why?
|
Adult | 2 | 2016 | 11712 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2004 | 277 | 0.050 |
Why?
|
Mannans | 1 | 2020 | 3 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2002 | 515 | 0.050 |
Why?
|
Carbohydrate Sequence | 1 | 2020 | 22 | 0.050 |
Why?
|
Acetylglucosamine | 1 | 2020 | 7 | 0.050 |
Why?
|
Haemophilus influenzae | 1 | 2020 | 5 | 0.050 |
Why?
|
Persuasive Communication | 1 | 2000 | 8 | 0.050 |
Why?
|
Counseling | 1 | 2021 | 116 | 0.040 |
Why?
|
Chickens | 3 | 1989 | 133 | 0.040 |
Why?
|
Women's Health | 1 | 2000 | 145 | 0.040 |
Why?
|
Polysaccharides | 1 | 2020 | 58 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 1999 | 33 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 2000 | 225 | 0.040 |
Why?
|
Flow Cytometry | 2 | 2000 | 399 | 0.040 |
Why?
|
alpha-2-Antiplasmin | 1 | 1999 | 1 | 0.040 |
Why?
|
Antigen-Antibody Reactions | 1 | 1999 | 20 | 0.040 |
Why?
|
Recombinant Fusion Proteins | 1 | 2000 | 295 | 0.040 |
Why?
|
Consensus Sequence | 1 | 1998 | 24 | 0.040 |
Why?
|
Plasmodium falciparum | 1 | 2000 | 135 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 1999 | 185 | 0.040 |
Why?
|
Oligopeptides | 1 | 2018 | 102 | 0.040 |
Why?
|
Primary Health Care | 1 | 2021 | 294 | 0.040 |
Why?
|
Stereoisomerism | 1 | 1998 | 167 | 0.040 |
Why?
|
Interferon-gamma | 1 | 1999 | 250 | 0.040 |
Why?
|
Coated Materials, Biocompatible | 1 | 2017 | 19 | 0.040 |
Why?
|
Adolescent | 3 | 2021 | 5363 | 0.040 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 1997 | 16 | 0.040 |
Why?
|
Diglycerides | 1 | 2017 | 10 | 0.040 |
Why?
|
Drug Design | 1 | 2018 | 162 | 0.040 |
Why?
|
Cardiolipins | 1 | 2017 | 11 | 0.040 |
Why?
|
Oxidative Stress | 1 | 2023 | 938 | 0.040 |
Why?
|
Transcription, Genetic | 2 | 2003 | 578 | 0.040 |
Why?
|
Receptor, IGF Type 2 | 1 | 1997 | 7 | 0.040 |
Why?
|
Fibrinolysin | 1 | 1997 | 8 | 0.040 |
Why?
|
Thymidine | 1 | 1997 | 15 | 0.040 |
Why?
|
Biotransformation | 1 | 2017 | 67 | 0.040 |
Why?
|
Probiotics | 1 | 2017 | 25 | 0.040 |
Why?
|
Spinal Cord Injuries | 1 | 2017 | 56 | 0.040 |
Why?
|
Protein Binding | 1 | 2020 | 972 | 0.040 |
Why?
|
Phylogeny | 1 | 2020 | 644 | 0.040 |
Why?
|
Triglycerides | 1 | 2017 | 138 | 0.040 |
Why?
|
DNA Fragmentation | 1 | 1997 | 92 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2017 | 171 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 1997 | 54 | 0.040 |
Why?
|
Metabolomics | 1 | 2017 | 81 | 0.040 |
Why?
|
Proteins | 1 | 1999 | 369 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2017 | 119 | 0.030 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 1996 | 41 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2017 | 448 | 0.030 |
Why?
|
Electric Conductivity | 1 | 2015 | 51 | 0.030 |
Why?
|
Electrodes | 1 | 2015 | 45 | 0.030 |
Why?
|
Equipment Design | 1 | 2015 | 124 | 0.030 |
Why?
|
Interleukin-2 | 1 | 1996 | 89 | 0.030 |
Why?
|
Cations, Divalent | 1 | 1995 | 24 | 0.030 |
Why?
|
Edetic Acid | 1 | 1995 | 23 | 0.030 |
Why?
|
Trypsin | 1 | 1995 | 38 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 1995 | 91 | 0.030 |
Why?
|
Birds | 1 | 1995 | 28 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 1995 | 56 | 0.030 |
Why?
|
Oxides | 1 | 2015 | 89 | 0.030 |
Why?
|
Pediococcus | 1 | 1973 | 1 | 0.030 |
Why?
|
Fructose-Bisphosphate Aldolase | 1 | 1973 | 3 | 0.030 |
Why?
|
Search Engine | 1 | 2013 | 6 | 0.030 |
Why?
|
Streptococcus | 1 | 1973 | 16 | 0.030 |
Why?
|
Pyruvic Acid | 1 | 2013 | 18 | 0.030 |
Why?
|
Lactobacillus | 1 | 1973 | 15 | 0.030 |
Why?
|
Ammonia | 1 | 2013 | 17 | 0.030 |
Why?
|
Models, Genetic | 2 | 2006 | 172 | 0.030 |
Why?
|
Linear Models | 1 | 2013 | 275 | 0.030 |
Why?
|
Adhesins, Escherichia coli | 1 | 2012 | 3 | 0.030 |
Why?
|
DNA | 1 | 1996 | 574 | 0.030 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2013 | 168 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2012 | 91 | 0.030 |
Why?
|
Cell Membrane Permeability | 2 | 1984 | 52 | 0.030 |
Why?
|
Receptors, Transferrin | 1 | 1992 | 15 | 0.030 |
Why?
|
G2 Phase | 1 | 1992 | 29 | 0.030 |
Why?
|
Calcitriol | 1 | 1992 | 31 | 0.030 |
Why?
|
Tretinoin | 1 | 1992 | 50 | 0.020 |
Why?
|
Antigens, CD | 1 | 1992 | 121 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 201 | 0.020 |
Why?
|
Bivalvia | 1 | 1991 | 21 | 0.020 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 132 | 0.020 |
Why?
|
Coumarins | 1 | 1991 | 38 | 0.020 |
Why?
|
Benzamides | 1 | 1991 | 78 | 0.020 |
Why?
|
Monocytes | 1 | 1992 | 257 | 0.020 |
Why?
|
Deoxyribonuclease I | 1 | 2009 | 25 | 0.020 |
Why?
|
Mitogens | 1 | 1989 | 10 | 0.020 |
Why?
|
Klebsiella pneumoniae | 1 | 2008 | 17 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2008 | 70 | 0.020 |
Why?
|
Kidney Tubules | 1 | 2008 | 33 | 0.020 |
Why?
|
Chemokine CCL2 | 1 | 2008 | 85 | 0.020 |
Why?
|
Nutritional Requirements | 1 | 1987 | 36 | 0.020 |
Why?
|
Diet Surveys | 1 | 1987 | 101 | 0.020 |
Why?
|
Rec A Recombinases | 1 | 2006 | 2 | 0.020 |
Why?
|
Endodeoxyribonucleases | 1 | 2006 | 29 | 0.020 |
Why?
|
Embryo, Nonmammalian | 2 | 1991 | 59 | 0.020 |
Why?
|
Gonorrhea | 1 | 2006 | 24 | 0.020 |
Why?
|
Cells, Cultured | 2 | 1999 | 1518 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 1987 | 242 | 0.020 |
Why?
|
Isoantigens | 1 | 1984 | 5 | 0.020 |
Why?
|
Antilymphocyte Serum | 1 | 1984 | 3 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1984 | 24 | 0.020 |
Why?
|
Complement System Proteins | 1 | 1984 | 21 | 0.020 |
Why?
|
Isopropyl Thiogalactoside | 1 | 2003 | 1 | 0.010 |
Why?
|
Cell Separation | 1 | 1984 | 93 | 0.010 |
Why?
|
Microscopy, Immunoelectron | 1 | 2003 | 34 | 0.010 |
Why?
|
Bursa of Fabricius | 1 | 1980 | 2 | 0.010 |
Why?
|
Methotrexate | 1 | 2000 | 23 | 0.010 |
Why?
|
Thymus Gland | 1 | 1980 | 81 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2000 | 136 | 0.010 |
Why?
|
Callithrix | 1 | 1999 | 9 | 0.010 |
Why?
|
Sepharose | 1 | 1999 | 15 | 0.010 |
Why?
|
Drug Resistance | 1 | 2000 | 99 | 0.010 |
Why?
|
Animals, Newborn | 1 | 1980 | 343 | 0.010 |
Why?
|
Luminescent Proteins | 1 | 1999 | 77 | 0.010 |
Why?
|
Plasmids | 1 | 2000 | 246 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 2000 | 181 | 0.010 |
Why?
|
Complement Fixation Tests | 1 | 1973 | 2 | 0.010 |
Why?
|
Electrophoresis, Disc | 1 | 1973 | 2 | 0.010 |
Why?
|
Immunoelectrophoresis | 1 | 1973 | 3 | 0.010 |
Why?
|
Immunodiffusion | 1 | 1973 | 4 | 0.010 |
Why?
|
Methods | 1 | 1973 | 13 | 0.010 |
Why?
|
Centrifugation, Density Gradient | 1 | 1973 | 22 | 0.010 |
Why?
|
Cell-Free System | 1 | 1973 | 15 | 0.010 |
Why?
|
Species Specificity | 1 | 1973 | 245 | 0.010 |
Why?
|
Binding, Competitive | 1 | 1991 | 111 | 0.010 |
Why?
|
Ovum | 1 | 1991 | 35 | 0.010 |
Why?
|
Spermatozoa | 1 | 1991 | 200 | 0.010 |
Why?
|
Nutritive Value | 1 | 1987 | 28 | 0.000 |
Why?
|
Minerals | 1 | 1987 | 47 | 0.000 |
Why?
|
Restaurants | 1 | 1987 | 39 | 0.000 |
Why?
|
Energy Intake | 1 | 1987 | 170 | 0.000 |
Why?
|
Sex Factors | 1 | 1987 | 898 | 0.000 |
Why?
|